Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular ...
Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...
Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.
KALAMAZOO, Mich. — Those who are recovering from addiction now have a new lifeline in Kalamazoo. Reach Sober Living has just ...
Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...
Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
The relatively new and less detectable product’s increasing prevalence among youth underscores an urgent need for informed ...
“People would sit in my chair, and any hairdresser… knows, that’s like therapy. And people are heavy, they’re carrying around ...
In the past, when someone was sentenced to substance-use-disorder (SUD) treatment in lieu of jail time in connection with ...
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit ...
The origins of autoimmune diseases like it are often mysterious, and an immune system that sees the body it inhabits as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback